Literature DB >> 15377549

A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration.

A M Armbrecht1, P A Aspinall, B Dhillon.   

Abstract

AIMS: (1) A prospective study to assess visual function measures and quality of life (QoL) in patients with wet age related macular degeneration (AMD) treated with photodynamic therapy (PDT). (2) To assess if PDT prevents severe visual loss (loss of six or more lines of distance visual acuity) in the treated eye.
METHODS: 48 of 51 recruited patients with predominantly classic subfoveal choroidal neovascularisation (CNV) secondary AMD who were treated with PDT were followed up for 1 year. Assessment included distance and near visual acuity, contrast sensitivity, vision related quality of life and fluorescein angiography. Photodynamic therapy using Visudyne was carried out according to standard protocol. Patients were followed up every 3 months and treatment repeated if there was significant leakage from CNV.
RESULTS: At the 12 month follow up, 71% (n = 34) of the patients lost less than three lines of best corrected distance visual acuity. Although there were significant decreases in some of the QoL items tested, patients were significantly less anxious and more independent outdoors at the 12 month follow up.
CONCLUSION: This study is in keeping with published literature with PDT preventing severe visual loss in two thirds of treated patients with predominantly classic CNV.

Entities:  

Mesh:

Year:  2004        PMID: 15377549      PMCID: PMC1772343          DOI: 10.1136/bjo.2003.038604

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

Review 1.  Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.

Authors:  U Schmidt-Erfurth; T Hasan
Journal:  Surv Ophthalmol       Date:  2000 Nov-Dec       Impact factor: 6.048

Review 2.  New treatments in age-related macular degeneration.

Authors:  Claire Y Hooper; Robyn H Guymer
Journal:  Clin Exp Ophthalmol       Date:  2003-10       Impact factor: 4.207

3.  Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia.

Authors:  M B Parodi; S Da Pozzo; G Ravalico
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

4.  Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1993-09

5.  Cataract surgery in patients with age-related macular degeneration: one-year outcomes.

Authors:  Ana Maria Armbrecht; Catherine Findlay; Peter Alan Aspinall; Adrian Robert Hill; Baljean Dhillon
Journal:  J Cataract Refract Surg       Date:  2003-04       Impact factor: 3.351

6.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

7.  Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.

Authors:  U Schmidt-Erfurth; J W Miller; M Sickenberg; H Laqua; I Barbazetto; E S Gragoudas; L Zografos; B Piguet; C J Pournaras; G Donati; A M Lane; R Birngruber; H van den Berg; H A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler
Journal:  Arch Ophthalmol       Date:  1999-09

8.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

9.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

10.  Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.

Authors:  Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donati; Gary Edd Fish; Laurie A Haynes; Hilel Lewis; Joan W Miller; Jordi M Monés; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenburg; Lawrence J Singerman; Jason S Slakter; Andrew Strong; Stéphane Vannier
Journal:  Arch Ophthalmol       Date:  2002-10
View more
  13 in total

1.  Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration--a report of 1 year results.

Authors:  Matthias Lüke; Focke Ziemssen; Karl Ulrich Bartz-Schmidt; Faik Gelisken
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-09       Impact factor: 3.117

Review 2.  Age-related macular degeneration and recent developments: new hope for old eyes?

Authors:  Brid Morris; Fraser Imrie; Ana-Maria Armbrecht; Baljean Dhillon
Journal:  Postgrad Med J       Date:  2007-05       Impact factor: 2.401

3.  Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life.

Authors:  Alex W Hewitt; V Swetha Jeganathan; Juanita E Kidd; Konrad Pesudovs; Nitin Verma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

Review 4.  Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.

Authors:  Sandra Maksys; Sibylla Richter-Müksch; Birgit Weingessel; Pia Veronika Vécsei-Marlovits
Journal:  Wien Klin Wochenschr       Date:  2016-08-22       Impact factor: 1.704

6.  Validation and comparison of five preference-based measures among age-related macular degeneration patients: evidence from mainland China.

Authors:  Yanhui Si; Shunping Li; Yanjiao Xu; Gang Chen
Journal:  Qual Life Res       Date:  2021-12-02       Impact factor: 4.147

7.  Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT).

Authors:  Matthias Lüke; Focke Ziemssen; Michael Völker; Elke Altpeter; Julia Beutel; Dorothea Besch; Karl Ulrich Bartz-Schmidt; Faik Gelisken
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-12       Impact factor: 3.117

8.  Determinants of patient satisfaction with photodynamic therapy for neovascular age-related macular degeneration or polypoidal choroidal vasculopathy.

Authors:  Kenji Yamashiro; Akitaka Tsujikawa; Akihiro Nishida; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2007-10-05       Impact factor: 2.447

9.  Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools.

Authors:  Robert P Finger; Monika Fleckenstein; Frank G Holz; Hendrik P N Scholl
Journal:  Qual Life Res       Date:  2008-05       Impact factor: 4.147

10.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.